Drug intelligence / Profile preview

Daily recombinant human growth hormone

Development stage: Unknown
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Daily recombinant human growth hormone (DGH) is a pharmaceutical drug administered via daily subcutaneous injections. It serves as the standard of care therapy for children with growth hormone deficiency (GHD). DGH works by replacing endogenous growth hormone, thereby stimulating linear growth and influencing metabolic processes. Its efficacy and safety profile are often compared with newer long-acting growth hormone formulations.

Other names: Daily growth hormone

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on Daily recombinant human growth hormone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daily recombinant human growth hormone.

Explore the full profile